There has been back-and-forth on the health risks of light or moderate alcohol consumption. Recent reviews have tried to narrow down the cancer risks associated with drinking. Also, the heart benefits of GLP-1s like Ozempic and Wegovy could be dependent on your BMI, based on a new study in people with type 2 diabetes. And an update from the Australian Health Practitioner Regulation Agency (AHPRA) on GLP-1 prescribing practices. ReferencesAlcohol and Cancer Risk - JAMA InsightsReview of Evidence on Alcohol and Health - National Academies of Sciences, Engineering, and MedicineGLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes Incidence of GLP‐1 receptor agonist use by women of reproductive age attending general practices in Australia, 2011–2022: a retrospective open cohort studyJoint statement on professional responsibilities for prescribing and dispensing medicines - AHPRA

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related